659MO Pembrolizumab with or without chemotherapy for first-line treatment of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): 5-year results from KEYNOTE-048.

Autor:	Tahara, M.1 (AUTHOR), Greil, R.2 (AUTHOR), Rischin, D.3 (AUTHOR), Harrington, K.J.4 (AUTHOR), Burtness, B.5 (AUTHOR), De Castro, G.6 (AUTHOR), Psyrri, A.7 (AUTHOR), Brana, I.8 (AUTHOR), Neupane, P.9 (AUTHOR), Bratland, Å.10 (AUTHOR), Fuereder, T.11 (AUTHOR), Hughes, B.G.M.12 (AUTHOR), Mesia Nin, R.13 (AUTHOR), Ngamphaiboon, N.14 (AUTHOR), Rordorf, T.15 (AUTHOR), Wan Ishak, W.Z.16 (AUTHOR), Lin, J.17 (AUTHOR), Gumuscu, B.17 (AUTHOR), Lerman, N.17 (AUTHOR), Soulieres, D.18 (AUTHOR)
Zdroj:	Annals of Oncology. 2022 Supplement 7, Vol. 33, pS844-S844. 1p.
Databáze:	Academic Search Ultimate
Externí odkaz:	Zobrazit plný text záznamu